Cargando…

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I

Antibodies against recombinant proteins can significantly reduce their effectiveness in unanticipated ways. We evaluated the humoral response of mice with the lysosomal storage disease mucopolysaccharidosis type I treated with weekly intravenous recombinant human alpha-l-iduronidase (rhIDU). Unlike...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Steven Q., Kan, Shih-hsin, Clarke, Don, Sanghez, Valentina, Egeland, Martin, Vondrak, Kristen N., Doherty, Terence M., Vera, Moin U., Iacovino, Michelina, Cooper, Jonathan D., Sands, Mark S., Dickson, Patricia I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684429/ https://www.ncbi.nlm.nih.gov/pubmed/29159202 http://dx.doi.org/10.1016/j.omtm.2017.09.008

Ejemplares similares

Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice
por: Clarke, Don, et al.
Publicado: (2018)

Brain transplantation of genetically corrected Sanfilippo type B neural stem cells induces partial cross-correction of the disease
por: Pearse, Yewande, et al.
Publicado: (2022)

Notch activation is required for downregulation of HoxA3-dependent endothelial cell phenotype during blood formation
por: Sanghez, Valentina, et al.
Publicado: (2017)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I
por: Khalid, Omar, et al.
Publicado: (2016)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience
por: Clarke, Lorne A., et al.
Publicado: (2020)

Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve Replacement
por: Sherwood, Dalton J., et al.
Publicado: (2021)

Distribution of Heparan Sulfate Oligosaccharides in Murine Mucopolysaccharidosis Type IIIA
por: Mason, Kerryn, et al.
Publicado: (2014)

Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA
por: Pericleous, Kleopatra, et al.
Publicado: (2023)

Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB
por: Ellinwood, N. Matthew, et al.
Publicado: (2022)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model
por: Sawamoto, Kazuki, et al.
Publicado: (2019)

Evaluation of commonly used ectoderm markers in iPSC trilineage differentiation
por: Kuang, Yu-Lin, et al.
Publicado: (2019)

Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
por: Lund, Troy C., et al.
Publicado: (2020)

A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I
por: Mendez, Daniel C, et al.
Publicado: (2015)

A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation
por: Perez, Harvey, et al.
Publicado: (2021)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I)
por: Barbosa Mendes, Ana, et al.
Publicado: (2019)

Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs
por: Simonaro, Calogera M., et al.
Publicado: (2016)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Arterial Pathology in Canine Mucopolysaccharidosis-I and Response to Therapy
por: Lyons, Jeremiah A., et al.
Publicado: (2011)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022)

The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure
por: Schiattarella, Gabriele Giacomo, et al.
Publicado: (2015)

12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment
por: Gabrielli, Orazio, et al.
Publicado: (2016)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Mucopolysaccharidosis-Plus Syndrome
por: Vasilev, Filipp, et al.
Publicado: (2020)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Hearing Loss in Mucopolysaccharidosis
por: Bicalho, Cibele Gomes, et al.
Publicado: (2021)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Perioperative airway management for aortic valve replacement in an adult with mucopolysaccharidosis type II (Hunter syndrome)
por: Suzuki, Kazuchika, et al.
Publicado: (2018)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs
por: Gawri, Rahul, et al.
Publicado: (2022)

Cathepsin B-associated Activation of Amyloidogenic Pathway in Murine Mucopolysaccharidosis Type I Brain Cortex
por: Viana, Gustavo Monteiro, et al.
Publicado: (2020)

Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II
por: Yamazaki, Narutoshi, et al.
Publicado: (2023)

Transcripts that associate with the RNA binding protein, DEAD-END (DND1), in embryonic stem (ES) cells
por: Zhu, Rui, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kpkkt54j9cd7l93dr4587gj25l